PharmaCyte Biotech Inc (PMCB) does not present a strong buy opportunity at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the technical indicators are mixed, the lack of significant positive catalysts, weak financial performance, and absence of trading signals suggest a hold position for now.

Technical Analysis

The MACD is positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 46.885, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.695, with resistance at 0.742 and support at 0.647. Overall, the technical outlook is mixed, leaning slightly bearish.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. No recent news, no significant hedge fund or insider activity, and no congress trading data available.

Neutral/Negative Catalysts

despite YoY improvements. Bearish moving averages and lack of significant trading sentiment or analyst ratings further weigh on the stock.

Financial Performance

In Q2 2026, the company reported no revenue growth (0% YoY), a net income of -$8,416,610 (up 184.45% YoY), and an EPS of -1.24 (up 217.95% YoY). Gross margin remains at 0%. While there are improvements in losses, the overall financials remain weak.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast PMCB stock price to rise

Buy

Hold

Sell

Current: 0.690

Low

Averages

High